These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34364162)

  • 1. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
    Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
    Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
    Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
    Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
    Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
    Bhatia N; Hazra S; Thareja S
    Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment.
    Gobbi S; Martini S; Rozza R; Spinello A; Caciolla J; Rampa A; Belluti F; Zaffaroni N; Magistrato A; Bisi A
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-aromatase and anti-estrogenic activity of plant products in the treatment of estrogen receptor-positive breast cancer.
    Verhoog NJD; Spies LL
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106581. PubMed ID: 38997071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-positive (ER
    Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
    Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
    Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
    Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
    Saha T; Makar S; Swetha R; Gutti G; Singh SK
    Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?
    Bhattacharya P; Abderrahman B; Jordan VC
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):297-310. PubMed ID: 28281842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
    Clusan L; Le Goff P; Flouriot G; Pakdel F
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERα-targeted endocrine therapy, resistance and the role of GPER.
    Pepermans RA; Prossnitz ER
    Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
    Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
    Front Chem; 2019; 7():602. PubMed ID: 31552220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.